Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway

Therapies targeting epidermal growth factor receptor (EGFR) can effectively treat with non-small cell lung cancer (NSCLC), but NSCLC’s drug resistance makes it intractable. Herein, we showed that RU486 metabolite metapristone inhibited the proliferation of various NSCLC cell lines with either wild (...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Jingwei, Zheng, Guirong, Chen, Hongning, Liu, Jian, Xu, Aixiao, Chen, Fan, Li, Tao, Lu, Yusheng, Xu, Jianguo, Zheng, Ning, Jia, Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667967/
https://www.ncbi.nlm.nih.gov/pubmed/29108234
http://dx.doi.org/10.18632/oncotarget.18640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667967/
https://www.ncbi.nlm.nih.gov/pubmed/29108234
http://dx.doi.org/10.18632/oncotarget.18640

Ejemplares similares